Please visit answersincme.com/PRH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in nephrology discusses the guideline-recommended approach to incorporating non-steroidal mineralocorticoid receptor antagonists (MRAs) into the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Describe the role of non-steroidal MRAs in the treatment of patients with CKD and T2D; Evaluate the clinical impact of the latest safety and efficacy data for novel non-steroidal MRAs in patients with CKD and T2D; Review the latest guideline updates informing the use of novel non-steroidal MRAs in patients with CKD and T2D; Identify patients with CKD and T2D who might benefit from treatment with novel non-steroidal MRAs; and Formulate treatment plans for patients with CKD and T2D that incorporate the latest evidence and guideline updates for non-steroidal MRAs.